SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.834
NA - Nord America 1.804
EU - Europa 534
SA - Sud America 415
AF - Africa 83
OC - Oceania 5
Totale 4.675
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.714
SG - Singapore 664
CN - Cina 306
BR - Brasile 287
IT - Italia 223
VN - Vietnam 202
BD - Bangladesh 186
HK - Hong Kong 183
DE - Germania 73
IN - India 61
MX - Messico 47
AR - Argentina 43
FR - Francia 42
ZA - Sudafrica 38
ID - Indonesia 34
JP - Giappone 34
RU - Federazione Russa 32
FI - Finlandia 30
UA - Ucraina 29
GB - Regno Unito 28
CA - Canada 27
IQ - Iraq 25
EC - Ecuador 23
CO - Colombia 22
TR - Turchia 21
MY - Malesia 18
NL - Olanda 17
ES - Italia 15
MA - Marocco 13
PH - Filippine 13
VE - Venezuela 13
PK - Pakistan 12
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
AT - Austria 8
CL - Cile 8
TN - Tunisia 8
NP - Nepal 7
UZ - Uzbekistan 7
BO - Bolivia 6
DZ - Algeria 6
AU - Australia 5
IE - Irlanda 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
UY - Uruguay 5
AL - Albania 4
CH - Svizzera 4
JO - Giordania 4
OM - Oman 4
PL - Polonia 4
PY - Paraguay 4
TH - Thailandia 4
BG - Bulgaria 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
EG - Egitto 3
ET - Etiopia 3
IL - Israele 3
JM - Giamaica 3
LT - Lituania 3
PA - Panama 3
PE - Perù 3
SN - Senegal 3
AO - Angola 2
AZ - Azerbaigian 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
KE - Kenya 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
SE - Svezia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
BB - Barbados 1
BY - Bielorussia 1
CR - Costa Rica 1
GR - Grecia 1
HN - Honduras 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
MU - Mauritius 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
Totale 4.675
Salva come PNG Salva come JPEG
Città #
Santa Clara 428
Singapore 371
San Jose 300
Hong Kong 182
Ashburn 170
New York 91
Ho Chi Minh City 72
Beijing 69
Council Bluffs 47
Hanoi 43
Los Angeles 37
Mexico City 37
Tokyo 34
Bologna 27
Milan 24
Lauterbourg 23
Dallas 21
Lappeenranta 21
São Paulo 21
Chicago 19
Jakarta 19
Fairfield 17
Hefei 17
Orem 17
Rome 15
Buffalo 13
Cambridge 13
London 13
Chennai 11
Da Nang 11
Dhaka 11
Ferrara 11
Kuala Lumpur 11
Munich 11
Salt Lake City 11
Baghdad 10
Brooklyn 10
Seattle 10
Guayaquil 9
Montreal 9
San Francisco 9
Houston 8
Naples 8
Palermo 8
Phoenix 8
Rio de Janeiro 8
Curitiba 7
Elk Grove Village 7
Las Vegas 7
Medellín 7
Paris 7
Amsterdam 6
City of London 6
Falkenstein 6
Fortaleza 6
Frankfurt am Main 6
Helsinki 6
Johannesburg 6
Salvador 6
Tashkent 6
Thái Bình 6
Woodbridge 6
Atlanta 5
Brasília 5
Caracas 5
Forest City 5
Lahore 5
Moscow 5
Quito 5
Sydney 5
Ankara 4
Assago 4
Bangkok 4
Bari 4
Bhopal 4
Bishkek 4
Boardman 4
Bogotá 4
Bình Dương 4
Delhi 4
Denver 4
Detroit 4
Dublin 4
Haiphong 4
La Paz 4
Manila 4
Montevideo 4
Muscat 4
New Delhi 4
Newark 4
Nuremberg 4
Santiago 4
Sorocaba 4
Addis Ababa 3
Agadir 3
Algiers 3
Amman 3
Belo Horizonte 3
Biên Hòa 3
Buenos Aires 3
Totale 2.589
Salva come PNG Salva come JPEG
Nome #
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 135
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 119
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 91
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 90
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 86
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 78
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 74
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 74
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 72
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 71
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 70
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients 70
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 70
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review 68
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 68
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 67
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 67
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 66
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 65
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 63
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 63
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 63
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 61
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 61
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 61
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 61
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 61
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 60
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 59
The application of cancer stem cell model in malignant mesothelioma 58
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 57
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 57
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 57
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 57
Bortezomib: A new pro-apoptotic agent in cancer treatment 56
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 56
The likelihood of being helped or harmed obtained from clinical trial results for cancer therapy: Can it really help? 55
A headlight on liquid biopsies: a challenging tool for breast cancer management 55
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 55
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 55
Anti-endothelin drugs in solid tumors 53
To ablate or not to ablate? Outcomes of local ablative treatments (LAT) for oncogene addicted (OA) oligo-metastatic (OM) non-small cell lung cancer (NSCLC): A systematic review 52
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 52
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 51
Cancer and the microbiome: Potential applications as new tumor biomarker 48
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 47
The Association Between Hepatocellular Carcinoma and Gastrointestinal Adenocarcinoma: Is This a New Syndrome in Patients With Cirrhosis? A Case Series 45
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 44
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 38
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 37
P3.14.06 Attitude of Italian Physicians Towards Germline and Somatic Genetic Testing in Pleural Mesothelioma: Preliminary Results of a Nationwide Survey 36
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 32
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 32
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 32
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 32
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 31
Targeted therapies in hepatocellular carcinoma 30
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 30
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 30
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 29
Monoclonal antibodies in gastrointestinal cancers 29
The role of 2D-Shearwave elastography in non invasive portal hypertension diagnosis 28
Well-being among Italian medical oncologists: An exploratory study 28
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 27
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 27
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 27
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival 27
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 26
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 26
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 26
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 26
Ramucirumab and its use in gastric cancer treatment 26
Multisciplinary management of patients with liver metastasis from colorectal cancer 25
What to look for in cell-free DNA from breast cancer patients 25
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 25
Dietary restriction: could it be considered as speed bump on tumor progression road? 25
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 25
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 25
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 25
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 25
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 24
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer 24
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 24
Editorial: Cancer biomarkers: molecular insights into diagnosis, prognosis, and risk prediction 24
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 24
HER2-positive male breast cancer: An update 24
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 23
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 23
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 22
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 22
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 21
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 21
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 21
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 21
Petals and thorns in programmed death-ligand 1 testing: Is all non–small cell lung cancer diagnostic material suitable? 21
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 20
New generation anaplastic lymphoma kinase inhibitors 20
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 20
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 20
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 20
Totale 4.475
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.349
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.349
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 1 0
2021/202214 2 0 5 0 2 0 0 0 1 0 2 2
2022/20235 1 0 1 0 1 0 0 0 0 0 1 1
2023/2024177 0 0 0 3 1 3 1 4 22 7 11 125
2024/20251.303 40 104 41 19 212 250 21 46 101 246 107 116
2025/20263.315 180 137 239 240 435 111 259 251 435 603 425 0
Totale 4.866